{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18"],"submitter":["Lucian Smith"],"journal":["Pharmaceutical research"],"pagination":["1174-1184"],"species":["Rattus norvegicus"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/MODEL0910130001"],"repository":["biostudies-other"],"additional_accession":["11587490"],"pubmed_authors":["Lucian Smith","Lukas Endler"]},"is_claimable":false,"name":"Grange2001 - PK interaction of L-dopa and benserazide","description":"<notes xmlns=\"http://www.sbml.org/sbml/level2/version4\">      <body xmlns=\"http://www.w3.org/1999/xhtml\">        <div class=\"dc:title\">Grange2001 - PK interaction of L-dopa and benserazide</div>            <div class=\"dc:description\">      <p>A pharmacokinetics of L-dopa in rats after administration of L-dopa alone (BIOMD0000000321) or L-dopa combined with a peripheral AADC (amino-acid-decarboxylase) inhibitor (this model: BIOMD0000000320) has been studied using noncompartmental analysis.</p>                </div>            <div class=\"dc:bibliographicCitation\">      <p>This model is described in the article:</p>                <div class=\"bibo:title\">        <a href=\"http://identifiers.org/pubmed/11587490\" title=\"Access to this publication\">A pharmacokinetic model to predict the PK inter","dates":{"release":"2009-10-29T00:00:00Z","modification":"2025-07-14T17:22:48.965Z","creation":"2025-03-31T12:23:57.612Z"},"accession":"MODEL0910130001","cross_references":{"biomodels___db":["BIOMD0000000320"],"kegg___compound":["C00355"],"reactome":["REACT_15382.1"],"chebi":["CHEBI:15765","CHEBI:25212"],"mamo":["MAMO_0000046"],"pubchem___compound":["2327","6047","188973","9307"],"go":["GO:0050892","GO:0042737","GO:0051583","GO:0030421","GO:0007588"],"doid":["DOID:14330"],"taxonomy":["10116"],"ec-code":["4.1.1.28","2.1.1.6"],"pubmed":["11587490"],"kegg___drug":["D03082"],"fma":["FMA:7563","FMA:76700"],"bto":["BTO:0000648"]}}